Gilder Gagnon Howe & Co’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-12,933
| Closed | -$812K | – | 277 |
|
|
2026
Q1 | $812K | Sell |
12,933
-1,064,288
| -99% | -$85.1M | 0.01% | 225 |
|
|
2025
Q4 | $103M | Sell |
1,077,221
-26,104
| -2% | -$2.56M | 1.08% | 26 |
|
|
2025
Q3 | $108M | Sell |
1,103,325
-21,928
| -2% | -$2.27M | 1.1% | 26 |
|
|
2025
Q2 | $121M | Sell |
1,125,253
-18,886
| -2% | -$1.91M | 1.28% | 19 |
|
|
2025
Q1 | $115M | Sell |
1,144,139
-72,258
| -6% | -$7.28M | 1.51% | 16 |
|
|
2024
Q4 | $109M | Sell |
1,216,397
-14,494
| -1% | -$1.28M | 1.17% | 21 |
|
|
2024
Q3 | $103M | Buy |
1,230,891
+102,151
| +9% | +$8.05M | 1.23% | 22 |
|
|
2024
Q2 | $86.9M | Buy |
+1,128,740
| New | +$82.6M | 1.09% | 27 |
|
|
2021
Q4 | – | Sell |
-20,644
| Closed | -$896K | – | 396 |
|
|
2021
Q3 | $896K | Sell |
20,644
-3
| -0% | -$133 | ﹤0.01% | 324 |
|
|
2021
Q2 | $883K | Sell |
20,647
-101
| -0.5% | -$4.25K | ﹤0.01% | 335 |
|
|
2021
Q1 | $802K | Sell |
20,748
-30
| -0.1% | -$1.14K | ﹤0.01% | 306 |
|
|
2020
Q4 | $747K | Sell |
20,778
-482
| -2% | -$17.4K | ﹤0.01% | 278 |
|
|
2020
Q3 | $812K | Sell |
21,260
-913
| -4% | -$35.2K | 0.01% | 267 |
|
|
2020
Q2 | $778K | Sell |
22,173
-856
| -4% | -$30.8K | 0.01% | 242 |
|
|
2020
Q1 | $751K | Sell |
23,029
-18,589
| -45% | -$726K | 0.01% | 202 |
|
|
2019
Q4 | $1.88M | Hold |
41,618
| – | – | 0.02% | 206 |
|
|
2019
Q3 | $1.69M | Sell |
41,618
-502
| -1% | -$21.3K | 0.02% | 210 |
|
|
2019
Q2 | $1.81M | Buy |
42,120
+259
| +0.6% | +$9.96K | 0.02% | 215 |
|
|
2019
Q1 | $1.61M | Sell |
41,861
-705
| -2% | -$26.9K | 0.02% | 202 |
|
|
2018
Q4 | $1.5M | Sell |
42,566
-93
| -0.2% | -$3.37K | 0.02% | 200 |
|
|
2018
Q3 | $1.64M | Sell |
42,659
-546
| -1% | -$19.1K | 0.02% | 209 |
|
|
2018
Q2 | $1.41M | Sell |
43,205
-154
| -0.4% | -$4.64K | 0.02% | 217 |
|
|
2018
Q1 | $1.19M | Sell |
43,359
-981
| -2% | -$26.7K | 0.01% | 219 |
|
|
2017
Q4 | $1.1M | Sell |
44,340
-1,656
| -4% | -$45.7K | 0.01% | 212 |
|
|
2017
Q3 | $1.34M | Sell |
45,996
-130
| -0.3% | -$3.59K | 0.02% | 197 |
|
|
2017
Q2 | $1.28M | Sell |
46,126
-950
| -2% | -$25.2K | 0.02% | 196 |
|
|
2017
Q1 | $1.17M | Sell |
47,076
-118
| -0.3% | -$2.87K | 0.02% | 190 |
|
|
2016
Q4 | $1.02M | Buy |
47,194
+16
| +0% | +$349 | 0.02% | 177 |
|
|
2016
Q3 | $1.12M | Hold |
47,178
| – | – | 0.02% | 185 |
|
|
2016
Q2 | $1.1M | Buy |
47,178
+311
| +0.7% | +$6.73K | 0.02% | 182 |
|
|
2016
Q1 | $882K | Sell |
46,867
-121
| -0.3% | -$2.13K | 0.02% | 170 |
|
|
2015
Q4 | $866K | Sell |
46,988
-136
| -0.3% | -$2.44K | 0.01% | 181 |
|
|
2015
Q3 | $773K | Sell |
47,124
-119
| -0.3% | -$2.03K | 0.01% | 196 |
|
|
2015
Q2 | $836K | Buy |
47,243
+1,186
| +3% | +$21.2K | 0.01% | 217 |
|
|
2015
Q1 | $818K | Buy |
46,057
+42
| +0.1% | +$664 | 0.01% | 209 |
|
|
2014
Q4 | $610K | Sell |
46,015
-2,831
| -6% | -$36.2K | 0.01% | 217 |
|
|
2014
Q3 | $577K | Sell |
48,846
-8,181,537
| -99% | -$103M | 0.01% | 226 |
|
|
2014
Q2 | $105M | Sell |
8,230,383
-414,825
| -5% | -$5.39M | 1.39% | 17 |
|
|
2014
Q1 | $117M | Buy |
8,645,208
+1,292,887
| +18% | +$17M | 1.59% | 19 |
|
|
2013
Q4 | $88.4M | Sell |
7,352,321
-54,960
| -0.7% | -$649K | 1.26% | 22 |
|
|
2013
Q3 | $87M | Buy |
7,407,281
+1,405,578
| +23% | +$15.2M | 1.36% | 20 |
|
|
2013
Q2 | $55.6M | Buy |
+6,001,703
| New | +$50.9M | 1.05% | 32 |
|
Other funds holding BSX
Gilder Gagnon Howe & Co's BSX Position: Q2 2026 in Review
Gilder Gagnon Howe & Co sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 12,933 shares — an estimated $812K sold.
Gilder Gagnon Howe & Co first reported a position in BSX in Q2 2013 and held it in 42 quarters. The position peaked at $121M in Q2 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Gilder Gagnon Howe & Co reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
- Gilder Gagnon Howe & Co sold 12,933 Boston Scientific shares in Q2 2026, an estimated $812K.
- Gilder Gagnon Howe & Co first reported a position in Boston Scientific in Q2 2013 and held it in 42 quarters.
- Gilder Gagnon Howe & Co's Boston Scientific position peaked at $121M in Q2 2025.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.